Takeda's final offer for Shire PLC stands; £46bn merger creates new top ten pharmaco

Following over a month of back and forth and four rejected offers, Shire PLC finally accepted a merger bid from Takeda Pharmaceutical Co. Ltd. The deal, which values Shire at about £46bn ($61.2bn; enterprise value of close to $80bn, including net debt), consists of $30.33 in cash and 0.839 of a new Takeda share or 1.678 Takeda ADSs for each outstanding Shire share, for an implied value per Shire share of £49.01 and a total of 44% cash and 56% equity.